The Probiotics in Pediatric Asthma Management (PROPAM) Study in the Primary Care Setting: A Randomized, Controlled, Double-Blind Trial with Ligilactobacillus salivarius LS01 (DSM 22775) and Bifidobacterium breve B632 (DSM 24706)

Table 2

Number and frequency of children with or without asthma exacerbations during the study.

	Placebo	Active treatment	OR (95%IC);
No exacerbation	160 (76.2%)	193 (91.0%)	3.17 (1.80–5.60); <0.001
At least one exacerbation	50 (23.8%)	19 (9.0%)
Less than two exacerbations	193 (91.9%)	207 (97.6%)	3.65 (1.32–10.08); 0.013
Two exacerbations	17 (8.1%)	5 (2.4%)